Senior Housing News November 6, 2024
Brain diagnostics company Amprion recently closed $6 million from a $15 million total Series B financing round to expand the company’s commercial reach and enhance dementia research and treatment.
Amprion diagnostics have the capacity to detect small amounts of “misfolded proteins” and is the only validated seed amplification available to aid in the diagnosis of Parkinson’s disease, Lewy body dementia and Alzheimer’s disease.
“We are honored to have FVE and Lilly support our team as we work to advance precision medicine for neurodegenerative disorders,” said Russell Lebovitz, MD, PhD, CEO and co-founder of Amprion. “In addition, the strong interest by leading neurology centers and pharmaceutical companies in our mission is indicative of the confidence they have in our technology and...
Today's Sponsors
Today's Sponsor